Agentix Corp. (AGTX) Form 10-K — Jun 30, 2026
Agentix Corp reported no revenue for the fiscal year ended March 31, 2026, with research and development expenses decreasing to $125,079 from $180,987 in the prior year. The company disclosed a cash balance of just $771 and an accumulated deficit of $7,007,164, leading management to raise substantial doubt about its ability to continue as a going concern without additional financing. The clinical-stage biotech company, focused on metabolic disease treatments, noted that it has no full-time or part-time employees and operates from a virtual office.
Key figures
- Revenue
- 0
- Cash Position
- 771
- Shares Outstanding
- 40066951
- Rd Expenses
- 125079
- Professional Fees
- 252036
- Accumulated Deficit
- 7007164
- Rd Expenses Prior Year
- 180987
- General And Administrative Expenses
- 68072
- Liabilities To Vendors And Related Parties
- 3596282
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.